New drug - Intelence
Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more
Its reaction to any criticism of the great IT plan or any suggestion for change is the political equivalent of sticking its fingers in its ears and going ‘la la la’ before declaring ‘No! Shan’t!’ repeatedly.
Widespread criticism from experts and stakeholders in other areas has seen major government projects dropped, ministers resigning and in one case the wholesale reform of a government department. But not so with Connecting for Health and the NPfIT.
It seems to have ignored calls for change by IT experts and survey findings, including some of GP’s own, that clinicians have not been engaged in the programme and remain unconvinced of its clinical benefit.
Concerns over the value of Choose and Book, the amount of time it takes up and whether the software works, have been dismissed as the rantings of luddites.
Yet it is difficult to find anyone connected with it to say any thing positive about the Connecting for Health projects.
Now even MPs are voicing concerns, with the Public Accounts Committee (PAC) producing what even the most generous souls would describe as a damning report, which includes evidence from the GP survey. The PAC criticises the DoH for the lack of any analysis of the benefits of NPfIT against its costs, the lack of a coherent timetable and its failure to engage clinicians in the project. In fact it says there is no sign that the programme will deliver tangible benefits during the the current contract period.
Such are the criticisms of the programme that one member of the PAC has called for it to be wound up immediately, although the report merely asks for an urgent review.
This time, the DoH has no excuse for another sulk. The MPs on the PAC are neither users of the system nor ‘disgruntled’ IT experts — perhaps it is time to listen to the facts.
Quick search - use * for an abbreviated search, eg nico*
Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more
Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more
Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more
Comments
Only registered users may comment. Log in now or register for a free account.